黑色素瘤靶点及其靶向治疗药物

The potential targeted therapeutic drugs for melanoma

黑色素瘤是整形外科常见的高度恶性肿瘤,发展迅速,预后差,在全球发病率逐年上升,死亡率居皮肤软组织肿瘤之首。近年黑色素瘤的靶向治疗药物发展迅猛,大幅提高了晚期患者预后,但当前的主流靶向药物单药治疗带来的疗效提升仍有限,总体缓解率约为20%。目前非一线、具有潜力的靶向药物的临床试验已经大量开展,向临床医生展现了这些药物和潜在靶点的价值。该文总结了黑色素瘤治疗的潜在靶点和具有潜力的药物的临床试验,旨在帮助临床医生更好地了解该疾病靶向治疗的前景,发现更多有效的治疗药物。

Melanoma is a common and highly malignant tumor with rapid development,poor prognosis and high mortality in the field of plastic surgery.The incidence rate around the world is increasing year by year and the mortality rate ranks first among skin and soft tissue tumors.The rapid development of targeted and immunotherapeutic drugs has greatly improved the prognosis of patients with advanced melanoma.Currently,the improvement of curative effect brought by monotherapy with mainstream targeted drugs is still limited,and the overall remission rate is about 20%.A large number of clinical trials of non first-line and potential targeted drugs have been carried out,showing the value of these drugs and potential targets to clinicians.This article mainly reviews the potential targets and clinical trials of melanoma,in order to help clinicians better understand the prospect of targeted treatments of the disease and find more effective therapeutic drugs.